Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-19-340

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional)

Closed on June 8, 2022.

Posted
August 12, 2019
Close date
June 8, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $416,925 in first-year total cost, median $416,925.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 BDCN-Q (55)]1

Most frequent institutions

  1. UNIV OF ARKANSAS FOR MED SCIS1
Competing awards under PAR-19-340 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021MnBuOE as a Novel Chemosensitizer for Breast Cancer and Neuroprotector1R01CA258673-01ALLEN, ANTINO RECIOUNIV OF ARKANSAS FOR MED SCIS, AR$416,925ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-19-340: Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional) | ScienceDex | ConductScience